c-Fms

CSF-1 receptor;colony stimulating factor 1 receptor;CSF-1R;CSF1R



c-FMS (CSF1R, CSF-1R) is located at the cell plasma membrane. c-FMS is the receptor for the ligand colony stimulating factor-1 (CSF1). c-FMS is an integral transmembrane glycoprotein that exhibits ligand-induced tyrosine-specific protein kinase activity, which triggers a signaling cascade eventually affecting transcription of CSF1-responsive genes. c-FMS tyrosine phosphorylation is induced upon binding of CSF1, leading to activation of Ras/Erk and class I-A phosphatidylinositol 3-kinase signaling pathways, which in turn activate the signal transducers and activators of transcription (STATs) pathways, specifically STAT1, STAT3, and STAT5. c-FMS activation by CSF1 results in increased growth, proliferation and differentiation.

c-Fms Inhibitors & Modulators

AZD7507

Cat. No.: HY-117244

Bioactivity: AZD7507 is a potent and orally active **CSF-1R** inhibitor, with antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



BLZ945

Cat. No.: HY-12768

Bioactivity: BLZ945 is a potent, selective and brain-penetrant **CSF-1R** inhibitor with an **IC_{50}** of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.

Purity: 99.56%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



c-Fms-IN-1

Cat. No.: HY-18791

Bioactivity: c-Fms-IN-1 is a **FMS kinase** inhibitor with an **IC_{50}** of 0.0008 μM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



c-Fms-IN-2

Cat. No.: HY-18787

Bioactivity: c-Fms-IN-2 is a **FMS kinase** inhibitor with an **IC_{50}** of 0.024 μM.

Purity: 99.05%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



c-Fms-IN-3

Cat. No.: HY-13075

Bioactivity: c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.

Purity: 99.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg



c-Fms-IN-6

Cat. No.: HY-111947

Bioactivity: c-Fms-IN-6 is a potent inhibitor of **c-FMS**, with an **IC_{50}** of ≤10 nM for unphosphorylated c-FMS, also weakly inhibits unphosphorylated c-KIT and PDGFR (**IC_{50}**, > 1 μM). Used in the research of autoimmune diseases [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg, 100 mg



c-Fms-IN-7

Cat. No.: HY-111948

Bioactivity: c-Fms-IN-7 is a **cFMS** inhibitor extracted from patent WO2011079076A1, example159, has an **IC_{50}** of 18.5 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



c-Fms-IN-8

Cat. No.: HY-119942

Bioactivity: c-Fms-IN-8 (compound 4a) is a **colony stimulating factor-1 receptor (CSF-1R, c-FMS)** Type II inhibitor, with an **IC_{50}** of 9.1 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



cFMS Receptor Inhibitor II

Cat. No.: HY-112451

Bioactivity: cFMS Receptor Inhibitor II is a **CSF1R** kinase inhibitor. CSF-1 is a cytokine [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg



CSF1R-IN-1

Cat. No.: HY-101774

Bioactivity: CSF1R-IN-1 is a **CSF1R** inhibitor with an with an **IC_{50}** of 0.5 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

CSF1R-IN-2

Cat. No.: HY-111787

Bioactivity: CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with **IC_{50}** values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Edicotinib

(JNJ-40346527)

Cat. No.: HY-109086

Bioactivity: Edicotinib is a selective and orally available **colony-stimulating factor-1 (CSF-1) receptor** inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GENZ-882706

(RA03546849)

Cat. No.: HY-101526

Bioactivity: GENZ-882706 is a potent colony stimulating factor-1 receptor (**CSF-1R**) Inhibitor extracted from patent WO 2017015267A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg



GENZ-882706(Raceme)

(GENZ-882706 racemate)

Cat. No.: HY-101526R

Bioactivity: GENZ-882706(Raceme) is the racemate of GENZ-882706.

Purity: 98.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg



GW2580

Cat. No.: HY-10917

Bioactivity: GW2580 is an orally bioavailable inhibitor of **c-Fms kinase** which completely inhibits human cFMS kinase in vitro at 0.06 μM.

Purity: 98.45%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



JTE-952

Cat. No.: HY-122906

Bioactivity: JTE-952 is a potent, oral active and selective Type II inhibitor of **colony stimulating factor-1 receptor** (**CSF-1R or cFMS**, type III receptor tyrosine kinase), with **IC_{50}** values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis...

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Ki20227

Cat. No.: HY-10408

Bioactivity: Ki-20227 is a highly selective c-Fms tyrosine kinase(CSF1R) inhibitor with IC50 value of 2 nM; 6 fold and > 100 fold selectivity over VEGFR2(IC50=12 nM) and c-Kit/PDGFRβ(IC50=451/217 nM), respectively. IC50 value: Target: CSF1R in vitro: Ki20227 did not inhibit other kinases...

Purity: 99.30%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg



OSI-930

Cat. No.: HY-10204

Bioactivity: OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. IC50 value: 9 nM(VEGFR2); 15 nM(CSF1R); 80 nM (Kit activated) [1] Target: VEGFR2/Kit/CSF1R in vitro: OSI-930...

Purity: 97.23%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



Pazopanib Hydrochloride

(GW786034 (Hydrochloride))

Cat. No.: HY-12009

Bioactivity: Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an **IC_{50}** of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Pexidartinib

(PLX-3397)

Cat. No.: HY-16749

Bioactivity: Pexidartinib (PLX-3397) is a potent, selective and ATP-competitive **CSF1R (cFMS)** and **c-Kit** inhibitor, with **IC_{50}**s of 20 and 10 nM, respectively. Pexidartinib exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other rela...

Purity: 99.64%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Pexidartinib hydrochloride

(PLX-3397 hydrochloride) Cat. No.: HY-16749A

Bioactivity: Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, selective and ATP-competitive **CSF1R (cFMS)** and **c-Kit** inhibitor, with **IC_{50}**s of 20 and 10 nM, respectively.

Pexidartinib exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Anti-cancer activity...

Purity: 99.50%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



PLX647

Cat. No.: HY-13838

Bioactivity: PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively. IC50 value: 28/16 nM(FMS/KIT) [1] Target: FMS/KIT dual inhibitor in vitro: PLX647 was tested against a panel of 400 kinases at a concentration of 1 μM, 35-fold above its FMS enzymatic IC50 and 60-fold above its KIT...

Purity: 98.20%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg